Mirum Pharmaceuticals (MIRM)
(Delayed Data from NSDQ)
$53.39 USD
+1.55 (2.99%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $59.50 +6.11 (11.44%) 4:36 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Fundamental Charts
About Return on Equity (TTM)
Mirum Pharmaceuticals, Inc.'s return on equity, or ROE, is -33.63% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.08%. While this shows that MIRM has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
MIRM 53.39 +1.55(2.99%)
Will MIRM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MIRM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MIRM
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
MIRM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Mirum Gains 35% in 3 Months: How Should You Play the Stock?
EMA Accepts GSK's Filing for Linerixibat in Rare Disease-Related Itch
Why Is Editas (EDIT) Up 40% Since Last Earnings Report?
Other News for MIRM
Here are the major earnings after the close Wednesday
Earnings Scheduled For August 6, 2025
Mirum Pharmaceuticals reports Q2 EPS (12c), consensus (33c)
ClearBridge Small Cap Growth Portfolios Q2 2025 Commentary
ClearBridge Small Cap Growth Fund Q2 2025 Commentary